CZMWF:OTC-Carl Zeiss Meditec AG (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 89.1

Change

0.00 (0.00)%

Market Cap

USD 9.34B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-15 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOF EssilorLuxottica Société ano..

+6.07 (+2.68%)

USD 105.29B
ESLOY Essilor International SA

+1.68 (+1.48%)

USD 104.03B
HOCPY Hoya Corp

+0.49 (+0.35%)

USD 48.28B
HOCPF HOYA Corporation

N/A

USD 48.05B
CLPBY Coloplast A

-0.20 (-1.51%)

USD 31.20B
CLPBF Coloplast A/S

N/A

USD 30.31B
TRUMF Terumo Corporation

+1.88 (+10.41%)

USD 27.88B
SAUHF Straumann Holding AG

+11.08 (+7.82%)

USD 24.11B
OCPNF Olympus Corporation

N/A

USD 21.30B
SRTOY Sartorius Stedim Biotech S.A

-1.34 (-6.50%)

USD 20.04B

ETFs Containing CZMWF

ZLI:CA BMO Low Volatility Intern.. 0.00 % 0.42 %

-0.08 (-0.30%)

CAD 0.30B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.95% 47% F 31% F
Dividend Return 1.11% 63% D 21% F
Total Return -15.85% 46% F 30% F
Trailing 12 Months  
Capital Gain -27.27% 37% F 36% F
Dividend Return 0.97% 41% F 13% F
Total Return -26.29% 37% F 36% F
Trailing 5 Years  
Capital Gain -11.21% 53% F 59% D-
Dividend Return 4.62% 18% F 16% F
Total Return -6.59% 49% F 57% F
Average Annual (5 Year Horizon)  
Capital Gain 6.10% 48% F 50% F
Dividend Return 6.81% 43% F 46% F
Total Return 0.71% 40% F 16% F
Risk Return Profile  
Volatility (Standard Deviation) 41.91% 59% D- 56% F
Risk Adjusted Return 16.24% 51% F 50% F
Market Capitalization 9.34B 70% C- 89% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.